Home/Pipeline/Fibromyalgia Biomarkers

Fibromyalgia Biomarkers

Fibromyalgia

DiscoveryActive

Key Facts

Indication

Fibromyalgia

Phase

Discovery

Status

Active

Company

Paradise Genomics

About Paradise Genomics

Paradise Genomics is a private, pre-revenue diagnostics company leveraging over 30 years of collective founder experience in genomics to discover novel biomarker signatures. The company emerged from GenUs BioSystems, a contract lab with a strong track record, and now aims to validate and commercialize its discoveries through partnerships with diagnostic and pharmaceutical companies. Its core value proposition is a proprietary bioinformatics process that claims unmatched sensitivity and precision in unlocking a unique region of the transcriptome for actionable genomic data.

View full company profile

Therapeutic Areas

Oncology Psychiatry Pain Management Gastroenterology

Other Fibromyalgia Drugs

Drug	Company	Phase	Status
SP-104	SCILEX	Preclinical/Phase 1	In development
Sequential Dialysis Technique	Halberd	Discovery	Conceptual
Stanza	Swing Therapeutics	Approved	Active
Fibromyalgia Studies	Pacific Clinical Research Medical Group	Phase 2/3	Active
SyqeAir Inhaler – Fibromyalgia	Syqe Medical	Commercial	Active
AXS-14	Axsome Therapeutics	Phase 3	Active
SP-104 (low-dose naltrexone DR capsules)	Scilex Holding	Preclinical	Development